Introduction
Following cannulation, the airway was mounted horizontally in an organ bath containing gassed (95 % O 2 and 5 % CO 2 ) Krebs solution (121 mM NaCl, 5.4 mM KCl, 1.2 mM MgSO 4 , 25 mM NaHCO 3 , 5 mM sodium morpholinopropane sulfonic acid, 11.5 mM glucose and 2.5 mM CaCl 2 ; pH 7.3) at 37 °C. The length of the segment was stretched to 105 % of its length in the fully deflated lung, shown previously to approximate the length at functional residual capacity (Noble et al., 2005) .
The proximal end of the airway lumen was connected to a reservoir filled with Krebs solution, the height of which set the initial P tm (5 cmH 2 O) and which was used to flush the lumen with Krebs solution between experiments. The distal end of the airway was connected to a liquid filled syringe pump. The syringe pump was capable of simulating breathing manoeuvres in 1-of-2 ways: fixed-P tm oscillations or fixed-volume oscillations (see below). All protocols were performed in a closed system, created by closure of a tap between the airway and the Krebs solution reservoir. The system was leak free with negligible compliance (0.0113 µL/cmH 2 O with a ~7.0 mL system volume).
Simulation of breathing manoeuvres
A custom-built servo-controlled syringe pump and pressure transducer were used to measure airway narrowing and to apply fixed-P tm oscillations (i.e. breathing manoeuvres), as previously described (Ansell et al., 2013; Noble et al., 2013; Noble et al., 2011) . Briefly, airways were connected to a 1 mL glass syringe driven by a feedback-controlled servomotor and motor controller and P tm was measured via a calibrated pressure transducer with feedback to the servomotor. Changes in airway luminal volume (i.e. airway narrowing and fixed-P tm oscillations) were measured via a calibrated displacement transducer that measured the rotation of the syringe motor. Using this approach, P tm was set to the desired level (i.e. static or oscillatory, see Experimental protocols) and ASM activation resulted in a decrease in lumen volume (i.e. airway narrowing, Figure 1A ). Measurement of ASM force and fixed-volume oscillations were applied using the same syringe pump oscillator described above but using the displacement transducer and not pressure transducer as the feedback control to the servomotor.
Using this approach, lumen volume does not decrease in response to ASM activation but instead results in an increase in P tm (i.e. active pressure) that represents ASM force production ( Figure   1B ). For comparisons with protocols that used fixed-P tm oscillations, the volume of oscillation (i.e. breathing manoeuvres) was that which produced the same trough to peak change in P tm in the contracted state (i.e. at the peak of contraction following the administration of the contractile agonist) and was fixed thereafter.
Experimental protocols
After dissection and mounting, airways were initially equilibrated to organ bath conditions for ~60 min under a static P tm of 5 cmH 2 O, approximating the mechanical environment present at functional residual capacity, in vivo. Viability of the tissue was confirmed through stimulation with acetylcholine (ACh, 10 -4 M) added to the organ bath. Airways were subsequently contracted to a single dose of CCh (10 -6 M) under both static (5 cmH 2 O P tm ) and oscillatory conditions in a randomised order. For the fixed-P tm approach, the oscillatory protocol comprised continuous large breathing manoeuvres (∆15 cmH 2 O at 0.25Hz). For the fixed-volume approach, the volume changes used were adjusted for each airway so that breathing manoeuvres were ∆15 cmH 2 O in the contracted state. The initial volume change needed to produce a ∆15 cmH 2 O after contraction was approximated from previously published experiments (Noble et al., 2007) . After the contraction plateaued, the oscillation volume was adjusted (if needed) to give a ∆15 cmH 2 O pressure swing. Tissues were oscillated for 6 min before contraction to CCh. Once contraction to CCh had plateaued, full dose-response curves (DRC) were constructed to the non-specific β-agonist, isoprenaline (10 -7 to 3x 10 -5 M). Experiments conducted using the fixed-P tm or fixedvolume approaches were performed in separate groups of airways.
Morphometric analyses were carried out to estimate the magnitude of ASM strain produced by breathing manoeuvres, as previously described (Ansell et al., 2013 (Ansell et al., 2013; Noble et al., 2013) .
Analysis and statistics
Lumen volume (i.e. prior to the administration of CCh) was measured by the volume that could be withdrawn until closure in the relaxed airway at 5 cmH 2 O P tm (Gunst et al., 1988) . Airway narrowing to CCh (for the fixed-P tm approach) was expressed as % lumen volume (where 100 % airway narrowing indicates airway closure). As described above, morphometry allowed the outer ASM perimeter (P mo ) to be calculated using the following equation:
The equation assumes WA i is constant at all P tm , that P mo is circular and that the lumen is cylindrical. Active pressure to CCh (for the fixed-volume approach) was expressed as ΔP tm .
Comparisons between static and oscillatory conditions were made at troughs of the oscillation cycle (volume or pressure, depending on the approach used). The response to isoprenaline was also expressed as % of the response to CCh (i.e. % contracted). Dose-response curves expressed as % contracted had variable slope sigmoidal curves fitted to individual airways. Sensitivity (PD 2 = -log 10 (EC 50 )) to isoprenaline were calculated for individual airways under static and oscillatory conditions. During fixed-P tm oscillations, ASM strain was calculated as ΔP mo /P mot , where ΔP mo is the tough to peak change in P mo during the breathing manoeuvre and P mot is the trough P mo immediately prior to the breathing manoeuvres.
Specific compliance of the airway wall was calculated from the Δvolume in relation to the ΔP tm during the inflationary limb of the tidal oscillation cycle using the equation: 
Results
Under static conditions, CCh (10 -6 M) produced 59.2 ± 4.9 % narrowing ( Figure 2A ) and 46.2 ± 2.5 cmH 2 O active pressure ( Figure 2B ). Isoprenaline (10 -7 to 3x 10 -5 M) reversed airway narrowing and active pressure in a dose-dependant manner. At the maximum dose of isoprenaline, airway narrowing fell to 39.1 ± 3.4 % narrowing and active pressure fell strongly to 2.6 ± 1.8 cmH 2 O under static conditions. Interestingly, when expressed as % of the response to CCh, the maximum reversal of active pressure with isoprenaline was greater than the maximum reversal airway narrowing (p<0.001).
Airways also stiffened strongly in response to CCh (p<0.001). following CCh for the fixed-P tm approach. Similarly, for the fixed-volume approach, specific compliance to fell from 0.0099 ± 0.0011 cmH 2 O -1 in the relaxed state, to 0.0014 ± 0.0002 cmH 2 O -1 following CCh. Isoprenaline reduced airway stiffness in a dose-dependent manner for both the fixed-P tm and fixed-volume approaches (Figure 3 ). Specific compliance increased to 0.0111 ± 0.0011 cmH 2 O -1 and 0.0065 ± 0.0007 for the fixed-P tm and fixed-volume approaches, respectively.
The magnitudes of oscillations (i.e. ∆P tm or ∆volume) used were chosen so that contraction prior to the administration of isoprenaline was not substantially attenuated. Airway narrowing and active pressure fell to 47.7 ± 5.3 % ( Figure 4A ) and 39.4 ± 3.7 cmH 2 O ( Figure 4B ) (compared to 59% and 46 cmH 2 O, see above) during fixed-P tm and fixed-volume oscillations, respectively.
There was no difference in sensitivity (PD 2 ) to isoprenaline under static, compared with oscillatory, conditions (Table 1) .
By comparing the bronchodilatory response to isoprenaline under static and oscillatory conditions, we sought to determine whether β 2 -agonists exerted a secondary bronchodilator effect by virtue of reducing airway wall stiffness and therefore, enhancing the bronchodilatory response to breathing manoeuvres. Our results demonstrate that the bronchodilatory response to isoprenaline was greater during fixed-P tm oscillations, compared with the response under static conditions ( Figure 5A ). At maximal dose of isoprenaline, airway narrowing fell to 10.4 ± 2.6 % (i.e. a ~82 % reversal from contracted) during breathing manoeuvres but to only 39.1 ± 3.4 % (i.e. a ~35 % reversal from contracted) under static conditions. The greater bronchodilatory response to isoprenaline during fixed-P tm oscillations is likely explained by the effect of isoprenaline on reducing airway wall stiffness, which increased ASM strain ( Figure 5B ), producing greater bronchodilation. Airway smooth muscle strain produced by fixed-P tm oscillations increased from 0.03 ±.0.003 (i.e. a 3 % increase in ASM perimeter) to 0.08 ± 0.007 (i.e. a 8 % increase in ASM perimeter) to isoprenaline in a dose-dependent manner.
In contrast to the experiments where P tm oscillations were held fixed, under conditions where fixed-volume oscillations were applied, ASM strain was constant for each airway at 0.01 ± 0.002 (i.e. a 1 % increase in ASM perimeter) and therefore, independent of changes in airway wall compliance produced by isoprenaline. Consequently, there was no difference in the response to isoprenaline under static, compared with oscillatory, conditions (Figure 6 ). At maximal dose of isoprenaline, active pressure fell to 2.6 cmH 2 O (i.e. a ~97 % reversal from contracted) during breathing manoeuvres and 2.3 cmH 2 O (i.e. a ~98 % reversal from contracted) under static conditions.
Discussion and conclusions
The present study determined whether pharmacological bronchodilators produce part of their physiological action through reduction of airway stiffness that enhances the relaxation produced by oscillatory loads. We show that the bronchodilatory response to isoprenaline was greater during simulated breathing manoeuvres, compared with the response under static conditions. We propose that the greater bronchodilatory response to isoprenaline during breathing manoeuvres is likely explained by the effect of isoprenaline on reducing airway wall stiffness, which increased ASM strain, producing greater bronchodilation.
In the present study, we used our established intact bronchial segment model. Our laboratory has previously modelled tidal breathing and DI manoeuvres in both animal (Ansell et al., 2013; Noble et al., 2007; West et al., 2012) and human (Noble et al., 2011) bronchial segments, including those from subjects with reported asthma (Noble et al., 2013) . The aforementioned studies simulate breathing manoeuvres by varying airway P tm . In the present study, the applied fixed-P tm oscillations modelled breathing manoeuvres (Δ15 cmH 2 O), larger than normal tidal breathing but less than a DI (Δ25 cmH 2 O). We assume that during bronchoconstriction, in vivo, P tm would increase above that occurring with normal tidal breathing in order to overcome the greater resistance of the respiratory system and to maintain minute ventilation. We induced ~59
% airway narrowing, which we calculate, assuming laminar flow, to be produce a substantial five to six-fold increase in airway resistance.
In order to establish a hypothesised synergy of isoprenaline and oscillation, we compared the bronchodilatory response to isoprenaline under static conditions and during breathing manoeuvres simulated by oscillating P tm . Isoprenaline produced greater bronchodilation (i.e.
reversal of airway narrowing) during fixed-P tm oscillations, with increasing separation from the static control with increasing dose of isoprenaline, suggesting a synergistic relationship. Since the bronchodilatory response to breathing manoeuvres is dependent on ASM strain (Ansell et al., 2013; Noble et al., 2007) and therefore, airway wall stiffness, our findings are likely explained by the effect of isoprenaline on reducing airway wall stiffness, which increased ASM strain. As discussed below, synergism was only revealed when oscillations of fixed-P tm were used, whereas fixed-volume oscillations did not alter the response to isoprenaline.
Studies from our laboratory (Ansell et al., 2009a) and others (Gump et al., 2001 ) have previously examined the combined effect of pharmacological bronchodilators when the strain applied to the ASM (length-change in isolated ASM strips or lumen volume in airway segments) is held fixed.
The principal conclusions drawn from these studies was that ASM length/volume oscillation and pharmacological bronchodilators act via separate pathways. That is, while both oscillation and pharmacological bronchodilators produced ASM relaxation, one did not affect the other.
However, in our prior study (Ansell et al., 2009a) we proposed one caveat: that pharmacological bronchodilators through their actions on reducing airway stiffness could theoretically maximise the strain-induced relaxation of ASM force, which we have now demonstrated by administering isoprenaline under fixed-P tm conditions. To further examine the mechanism underlying the greater bronchodilatory response to isoprenaline during simulated breathing manoeuvres, we again compared the relaxant response to isoprenaline during fixed-volume oscillations. Under conditions where fixed-volume oscillations were applied, and ASM strain was constant and therefore independent of changes in airway wall compliance produced by isoprenaline, there was no synergism between oscillatory and pharmacological pathways. This finding supports our proposal that the greater bronchodilatory response to isoprenaline during fixed-P tm oscillations (i.e. synergism) was mediated by reduced airway wall stiffness.
The increased drug efficacy during P tm oscillation is unlikely to be unique to isoprenaline, nor β 2 -agonists in general, rather, any pharmacological bronchodilator that reduces airway wall stiffness is predicted to undergo a similar synergy. We have previously shown in whole bronchial segments (Ansell et al., 2009a) in vitro, that nitric oxide (NO) also reverses ASM stiffness, and ASM cell stiffness is reduced in culture by numerous bronchodilator agonists such as isoproterenol, prostaglandin E 2 and forskolin amongst others (Hubmayr et al., 1996) . The synergy between pharmacological bronchodilation and breathing stresses is considered 'mechanical' through its dependence on ASM stiffness.
With the exception of the specific β 2 -agonist, salbutamol, in 1962 2 -agonist, salbutamol, in (Cullum et al., 1969 and the long-acting β 2 -agonist (LABA), salmeterol, in 1988 salmeterol, in (Ullman et al., 1988 , pharmacological bronchodilators have remained largely unchanged for 60 years. Not all patients with asthma respond well to current bronchodilator therapy (Wenzel, 2006) . Our finding that, at maximal dose, about half of the pharmacological bronchodilator effect is mediated by reduced airway wall stiffness has clinical implications for the treatment of asthma. Reducing airway wall stiffness represents a potential target for novel pharmacological agents (Bossé et al., 2010; Raqeeb et al., 2012; Seow, 2012) . Drug design models that consider the agonist's effects on the reversal of both ASM force and stiffness should lead to more effective pharmacological intervention.
Airway wall compliance and ASM strain were somewhat greater during fixed-P tm , compared with fixed-volume, oscillations. There are several possible explanations. Since the airway narrows in the fixed-P tm approach, the airway wall may operate at a more compliant region of the pressure-volume curve. In the pig, the airway wall is most compliant below 5 cmH 2 O P tm (at least in the relaxed state), before stiffening again at -5 cmH 2 O (Noble et al., 2002) . In comparison, the airway does not narrow in the fixed-volume approach and therefore, may operate at a comparatively stiffer region of the pressure volume curve. This explanation is not entirely sufficient, as there was a tendency for lower specific compliance during fixed-volume oscillations in the relaxed state. An alternative explanation is that the initial higher pressure swings in the fixed-P tm approach facilitated greater wall compliance. The volume oscillations were chosen such that pressure swings following the administration of CCh matched the Δ15 cmH 2 O in the fixed-P tm protocol, which meant that in the relaxed state pressure swings accompanying fixed-volume oscillations were considerably less (<4 cmH 2 O). The reduction in airway wall stiffness produced by isoprenaline also differed between the fixed-P tm and fixedvolume approaches, where the increase in compliance was greater during fixed-P tm oscillations, which may be explained by further 'softening' of the airway wall due to greater ASM strain.
The amplitudes of fixed-P tm and fixed-volume oscillations in the present study were chosen such that bronchoconstriction was not substantially attenuated by the breathing manoeuvres alone.
Fixed-P tm oscillations only modestly attenuated airway narrowing (~81 % of the response under static conditions), and there was a non-significant tendency towards reduced active pressure during volume oscillation (~85 % of the response under static conditions). During oscillations, the compliance of the airway wall determined the magnitude of ASM strain. Prior to the administration of isoprenaline, ASM strain during fixed-volume oscillations was ~1 %, compared with ~3 % during fixed-P tm oscillation, due to the difference in compliance between the fixed-P tm and fixed-volume approaches. Somewhat serendipitously, prior studies including those from our own laboratory suggest that strain between 1 -3% are necessary to affect the contractile apparatus (Ansell et al., 2013; Fredberg et al., 1997; Harvey et al., 2013; Noble et al., 2007) . Therefore, we are confident that the amplitudes of fixed-P tm and fixed-volume oscillations in the present study were sufficient to examine the bronchodilatory response to isoprenaline and ASM strain.
Several other interesting and potentially important aspects of this study require discussion.
During fixed-volume oscillations, active pressure was completely reversed by high doses of isoprenaline, however, airway wall stiffness had not returned to levels present in the relaxed state. Several studies have shown that, in response to contractile agonists, ASM stiffens prior to generating active force (Ansell et al., 2013; Pascoe et al., 2012) . Indeed, in whole bronchial segments, the sensitivity to acetylcholine is greater with respect to airway wall stiffening than active force or airway narrowing (Ansell et al., 2013) . The use of a sub-maximal dose of CCh in the present study likely produced a proportionally greater increase in airway wall stiffness than ASM contraction (i.e. airway narrowing or active pressure). The observation that isoprenaline was not able to completely reverse airway wall stiffening, compared with active force, may be due to the fact that there was more airway wall stiffening to reverse (note that the highest isoprenaline dose was chosen to produce maximum reversal of active force and airway narrowing, rather than airway wall stiffness). A similar disconnect between stiffness and airway narrowing during fixed-P tm oscillations was not observed, which may also be explained by further 'softening' of the airway wall due to greater ASM strain. Nonetheless, a scenario in which airway wall stiffening occurs prior to narrowing means that, during exacerbation of asthma, the bronchodilatory response to breathing manoeuvres becomes less effective early in the process.
Finally, our results showed that under static conditions, reversal of active pressure by isoprenaline was greater than the corresponding reversal of airway narrowing. As there was no difference in the dose of CCh or isoprenaline between protocols, we assume that cell signalling was comparable. However, ASM mechanics will be different at the level of the contractile apparatus, since ASM shortens in the fixed-P tm approach whilst in the fixed-volume approach the muscle contracts isometrically (i.e. no shortening). Airway smooth muscle is responsive to length-change, a phenomenon termed 'length adaptation' (Bossé et al., 2008; Seow, 2005) and it has been suggested that prolonged ASM shortening facilitates greater contraction (McParland et al., 2005) . In the present study, in the experiments where we measured airway narrowing, length adaptation may have occurred, producing a reduced bronchodilatory response to isoprenaline.
Whilst the present study cannot provide any further explanation as to why the bronchodilatory response to isoprenaline may be less effective in the experiments where we measured airway narrowing, the implication of these findings are that drug design models which measure ASM force, rather than airway narrowing may overestimate the effectiveness of pharmacological bronchodilators. A disconnect between ASM force and airway narrowing may also, at least in part, explain the discrepancies between experiments in isolated ASM strips and in vivo responses to breathing manoeuvres (Lutchen, 2013).
In conclusion, the present study found that, at maximal dose at least half of the bronchodilator effect of β 2 -agonists is mediated by reduced airway wall stiffness. To our knowledge, this is the first time that a secondary effect of a pharmacological bronchodilator has been experimentally shown and which is likely to be of clinical significance. The implications for the treatment of asthma are that reducing airway wall stiffness represents a potential second target for novel pharmacological agents. Table 1 . PD 2 to isoprenaline (10 -7 to 3x 10 -5 M) under static and oscillatory conditions.
Static Oscillatory
Fixed-P tm Approach Airway Narrowing Airway Narrowing 5.60 ± 0.11 6.00 ± 0.07
Fixed-Volume Approach Active Pressure Active Pressure
6.26 ± 0.14 7.78 ± 1.53
There was no difference in the sensitivity to isoprenaline for airway narrowing or active pressure under static, compared with oscillatory conditions. n = 6. Mean ± SEM. airway wall stiffness in a dose-dependant manner for both the fixed-P tm (p<0.001) and fixed-
